IL6R and COVID-19: Although the heterogenous pathologies likely have different mechanisms and therapeutic targets, it is promising that at least the pulmonary manifestations of COVID-19 are amenable to immunosuppressant treatment, such as dexamethasone and anti-IL-6R.